Delivery Order SPE2DB20D1100-SPE2DB24FC1B3

Award Date 6/4/24
Potential Completion Date 6/5/24
Potential Value $11K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of 4,564,529,550 units of HAVRIX 1,440 UNIT/ML SYRINGE/ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The Firm Fixed Price contract, valued at $2,758.38, was awarded to Amerisourcebergen Drug Corp's Corporate Office division, a major supplier of pharmaceuticals and medical supplies to the U.S. government. The contract has an ultimate completion date of May 8, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite...
This federal contract award is for the supply of HAVRIX 720 unit/0.5 mL syringes to the Defense Logistics Agency (DLA), a defense agency under the U.S. Department of Defense. The contract, valued at $3,143.04, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on April 24, 2024. The contract is a delivery order with a firm fixed price and an ultimate completion date of April 25, 2024. This award is not associated with a set-aside program. Amerisourcebergen Drug...
This federal contract award is for the delivery of HAVRIX 1,440 UNIT/ML SYRINGE to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense. The contract, valued at $18,540.74, was awarded to Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the federal government. The contract is a delivery order, with a firm fixed price pricing type, and an ultimate completion date of July 10, 2024. Amerisourcebergen holds a...
This federal contract award is to Amerisourcebergen Drug Corp's Corporate Office Division, a major supplier of pharmaceutical products and medical supplies to the U.S. government. The contract, valued at $21,214.10, is a Delivery Order placed by the Defense Logistics Agency (DLA), a defense agency, for the provision of HAVRIX 1,440 UNIT/ML SYRINGEML. The contract has a Firm Fixed Price pricing type and an Ultimate Completion Date of May 2, 2024. The award does not have a Set-Aside designation....
This federal contract award is for the delivery of HAVRIX 1,440 UNIT/ML SYRINGE, a pharmaceutical product, to the Defense Logistics Agency (DLA) Troop Support Medical. The $2,304.52 award was made to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on September 27, 2024. The contract is a firm-fixed price delivery order with a completion date of September 30, 2024. There is no set-aside designation for this award. Amerisourcebergen holds a significant Indefinite Delivery Contract...
This federal contract award is for the delivery of Havrix 1,440 units/mL syringes to the Defense Logistics Agency (DLA), a component of the U.S. Department of Defense. The $2,664.93 fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award is for the delivery of HAVRIX 1,440 UNIT/ML SYRINGEML, a pharmaceutical product, to the Defense Logistics Agency (DLA) by the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $3,395.20 firm fixed-price delivery order has a completion date of July 26, 2022 and was awarded on July 25, 2022. This contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award is for the delivery of HAVRIX 1,440 UNIT/ML SYRINGEML to the Defense Logistics Agency (DLA). The prime contractor is Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has a ceiling value of $3,667.40 and an ultimate completion date of April 21, 2023. It is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary of the...
This federal contract award is for the delivery of HAVRIX 1,440 UNIT/ML SYRINGEML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, and does not have a set-aside designation. The contract is a delivery order with a firm fixed price of $7,735.95 and a completion date of September 11, 2024. Amerisourcebergen has been awarded multiple Indefinite Delivery Contracts (IDCs) by the DLA and other...
This federal contract award is for the delivery of HAVRIX 720 UNIT/0.5 ML SYRINGE 0.5ML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $2,025.00, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of December 4, 2024. This award is not associated with a set-aside designation,...
  • SPE2DB20D1100
    Indefinite Delivery Contract
  • SPE2DB20D1100-SPE2DB24FC1B3
    Delivery Order

This federal contract award is for the delivery of HAVRIX 1,440 UNIT/ML SYRINGEML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $11,433.00 firm fixed-price contract was awarded to the Corporate Office division of Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on June 4, 2024. The award has an ultimate completion date of June 5, 2024 and is not designated as a set-aside.

Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The company also holds a smaller IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs, valued up to $750,000 through May 2024.

Generated 9/3/24, 12:14 PM